Haemonetics Corporation (HAE) Stock Analysis

Haemonetics Corporation (HAE) is a publicly traded company in the HEALTHCARE sector. It trades at $66.43, carries a market capitalization of $3.05B, a price-to-earnings ratio of 32.79. This page summarizes the public market data, fundamentals, and frequently asked questions for HAE, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - MEDICAL DEVICES

Exchange: NYSE

Key Metrics

• Price: $66.43
• Market Cap: $3.05B
• P/E Ratio: 32.79
• EPS: $2.05
• 52-Week High: $87.32
• 52-Week Low: $47.32

Market Sentiment

Haemonetics Corporation currently has a Bullish sentiment score of 0.17.

About Haemonetics Corporation

Haemonetics Corporation is a leading global healthcare company headquartered in Boston, Massachusetts, specializing in innovative medical products and solutions for blood and plasma collection, as well as surgical procedures. The company harnesses advanced technology to improve the quality and efficiency of healthcare delivery, addressing critical patient care needs through its diverse product portfolio. Committed to enhancing patient outcomes worldwide, Haemonetics is actively expanding its ...

GNG Research Analysis

GNG Research scores Haemonetics Corporation (HAE) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for HAE.

Frequently Asked Questions

Does HAE pay dividends?

Haemonetics Corporation (HAE) does not currently pay a regular dividend.

What is HAE's P/E ratio?

Haemonetics Corporation has a price-to-earnings (P/E) ratio of 32.79.

What is HAE's market cap?

Haemonetics Corporation (HAE) has a market capitalization of $3.05B with a current stock price of $66.43.